Related Experiment Videos
The human MDM-2 oncogene is overexpressed in leukemias
C E Bueso-Ramos1, Y Yang, E deLeon
1Hematopathology Program, University of Texas M.D. Anderson Cancer Center, Houston 77030-4095.
Blood
|November 1, 1993
Summary
MDM-2 gene amplification is not found in leukemia, but MDM-2 mRNA overexpression is common and linked to poor prognosis. This suggests alternative mechanisms drive MDM-2
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The MDM-2 gene product interacts with p53, regulating its activity.
- MDM-2 overexpression enhances tumorigenic potential and counteracts p53's tumor-suppressive functions.
- MDM-2 gene amplification is observed in about one-third of human sarcomas.
Purpose of the Study:
- To investigate the role of MDM-2 in leukemia by analyzing gene amplification and mRNA expression.
- To determine if MDM-2 alterations are associated with specific leukemia prognostic groups.
Main Methods:
- Analysis of MDM-2 gene amplification in 48 leukemia cases.
- Quantification of MDM-2 mRNA expression in 64 leukemia cases.
- Correlation of MDM-2 expression levels with karyotypic abnormalities and prognostic groups.
Main Results:
- No MDM-2 gene amplification was detected in any of the examined leukemia cases.
- Significant MDM-2 mRNA overexpression was observed in 53% (34 of 64) of leukemia cases.
- MDM-2 overexpression was associated with unfavorable chromosomal abnormalities, suggesting a role in leukemogenesis.
Conclusions:
- MDM-2 mRNA overexpression, not gene amplification, is a frequent alteration in human leukemias.
- Altered MDM-2 expression may contribute to leukemogenesis through mechanisms beyond gene amplification.
- MDM-2 dysregulation appears linked to unfavorable prognostic factors in leukemia.